|
Current issue
Archive
Online First
About the journal
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Special Issues
Instructions for authors
Publication charge
Editorial System
Submit your Manuscript
Open access 
|
4/2011
vol. 10 abstract:
Review paper
The use of micronized progesterone in menopausal hormonal therapy in the light of the most recent study results
Tomasz Paszkowski
,
Ewa Woźniakowska
,
Wojciech Wrona
,
Piotr Szkodziak
,
Tomasz Radomański
Przegląd Menopauzalny 2011; 4: 267–270
Online publish date: 2011/08/30
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Micronized progesterone (MP) can be used in the menopausal hormonal therapy (MHT). Micronized progesterone provides an effective endometrial protection during MHT. Hormonal therapy based on estrogen and vaginal progesterone results in the significant improvement of quality of life, elimination of menopausal symptoms and favorable changes of the blood lipids profile. Micronized progesterone does not adversely affect glucose metabolism and blood pressure. Progesterone seems to be safer for the breast as compared with other progestagens. The most recently published results indicate that MHT based on vaginal MP and transdermal estradiol constitutes the safest option of such therapy.
keywords:
micronized progesterone, menopausal hormonal therapy |
 |
